Business
Trading Update
MYCELX Technologies Corporation expects to achieve profitability in 2025, with revenue projected at approximately $11.7 million, a 140% increase over FY2024, though slightly below market expectations. The company anticipates EBITDA of around $680,000, a 131% improvement, including a $160,000 gain from the sale of its Saudi Arabia operations, and profit before tax of approximately $360,000, significantly exceeding market expectations of a loss. These results are attributed to cost discipline, operating leverage, and higher-margin revenue. Year-end cash and cash equivalents stand at $860,000, with an expected collection of $4 million in Q1 2026. The company is focusing on Produced Water, PFAS, and Water Services as core markets and has refined its management team with key promotions. Disclaimer*
About this update from Mycelx Technologies Corp.
The information contained within this Announcement is deemed by MYCELX Technologies Corporation to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014 as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018 ("MAR"). 20 January 2026 MYCELX Technologies Corporation ("MYCELX" or the "Company") MYCELX Achieves Profitability in 2025 Outperforming Market Expectations MYCELX Technologies Corporation (AIM: MYX), the clean water and clean air technology company, is pleased to provide a year-end financial update, reporting expected profitability that significantly exceeds market expectations, along with an update on the Company's strategy for its core markets. The Company expects FY2025 year-end revenue of c.a. $11.7 million, a 140% improvement over FY2024, although slightly less than market expectations of $12.5 million. While EBITDA and profit before tax ('PBT') remain subject to year-end closing procedures, the Company expects EBITDA to be in the region of $680,000, a 131% improvement over FY2024, which includes a gain of $160,000 from the sale of its Saudi Arabia operations, and $520,000 without the gain, compared to market expectations of an EBITDA loss of $200,000. PBT is expected to be in the region of $360,000, including the gain. This materially exceeds the market expectations of a PBT loss of $600,000. Excluding this gain, PBT is c.a. $200,000. This outperformance reflects strict cost discipline, operating leverage, and an increased contribution from higher-margin revenue. Cash and cash equivalents at year-end are $860,000, including $50,000 restricted cash. The Company also expects to collect approximately $4 million in cash during Q1 2026. Current Trading and Outlook We enter 2026 with a stronger earnings profile, a streamlined organization, and increasing commercial momentum across our core markets in the U.S. and internationally. The actions taken in 2024 and executed in 2025 have repositioned the Company for faster customer adoption, multiple project wins, and improved cash generation. Our relationships in the Middle East remain strong, and traction in the U.S. is accelerating following successful trials and deployments with both existing and new customers. We remain disciplined in...
View stock analysis, news, and events for Mycelx Technologies Corp.